IDEAYA Biosciences Inc (IDYA) Actualités

Biocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der...

IDEAYA hat die Option auf eine exklusive weltweite Lizenz für Biocytogens potenziell erstes bispezifisches Antikörper-Wirkstoff-Konjugat...

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific...

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 4, 2024 In the...

Form 8-K - Current report

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update PR...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a...

Form 8-K - Current report

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer...

Form 8-K - Current report

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities